Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Revisiting TP53 Mutations and Immunohistochemistry--A Comparative Study in 157 Diffuse Gliomas.

Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K.

Brain Pathol. 2015 May;25(3):256-65. doi: 10.1111/bpa.12173.

PMID:
25040820
2.

TP53 and p53 statuses and their clinical impact in diffuse low grade gliomas.

Gillet E, Alentorn A, Doukouré B, Mundwiller E, van Thuijl HF, Reijneveld JC, Medina JA, Liou A, Marie Y, Mokhtari K, Hoang-Xuan K, Sanson M, Delattre JY, Idbaih A.

J Neurooncol. 2014 May;118(1):131-9. doi: 10.1007/s11060-014-1407-4. Erratum in: J Neurooncol. 2014 Aug;119(1):225. Van Thuij, Hinke [corrected to van Thuijl, Hinke F].

PMID:
24590827
3.

Ethnicity delineates different genetic pathways in malignant glioma.

Chen P, Aldape K, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M.

Cancer Res. 2001 May 15;61(10):3949-54.

4.

Expression of p53 and prognosis in children with malignant gliomas.

Pollack IF, Finkelstein SD, Woods J, Burnham J, Holmes EJ, Hamilton RL, Yates AJ, Boyett JM, Finlay JL, Sposto R; Children's Cancer Group..

N Engl J Med. 2002 Feb 7;346(6):420-7.

5.

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ.

Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85.

6.

The differential diagnosis of pilocytic astrocytoma with atypical features and malignant glioma: an analysis of 16 cases with emphasis on distinguishing molecular features.

Cykowski MD, Allen RA, Kanaly AC, Fung KM, Marshall R, Perry A, Stolzenberg ED, Dunn ST.

J Neurooncol. 2013 Dec;115(3):477-86. doi: 10.1007/s11060-013-1249-5.

PMID:
24057326
7.

TP53 mutations in astrocytic gliomas: an association with histological grade, TP53 codon 72 polymorphism and p53 expression.

Faria MH, Neves Filho EH, Alves MK, Burbano RM, de Moraes Filho MO, Rabenhorst SH.

APMIS. 2012 Nov;120(11):882-9. doi: 10.1111/j.1600-0463.2012.02918.x.

PMID:
23009112
8.

Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression.

Reifenberger J, Ring GU, Gies U, Cobbers L, Oberstrass J, An HX, Niederacher D, Wechsler W, Reifenberger G.

J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31.

PMID:
8965097
9.

Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.

Sipayya V, Sharma I, Sharma KC, Singh A.

J Cancer Res Ther. 2012 Oct-Dec;8(4):598-601. doi: 10.4103/0973-1482.106567.

PMID:
23361281
10.

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Agarwal S, Sharma MC, Jha P, Pathak P, Suri V, Sarkar C, Chosdol K, Suri A, Kale SS, Mahapatra AK, Jha P.

Neuro Oncol. 2013 Jun;15(6):718-26. doi: 10.1093/neuonc/not015.

11.

p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.

van Meyel DJ, Ramsay DA, Casson AG, Keeney M, Chambers AF, Cairncross JG.

J Natl Cancer Inst. 1994 Jul 6;86(13):1011-7.

PMID:
8007011
12.

[Mutations of p53 gene in 41 cases of human brain gliomas].

Cui W, Kong X, Cao HL, Wang X, Gao JF, Wu RL, Wang XC.

Ai Zheng. 2008 Jan;27(1):8-11. Chinese.

PMID:
18184456
13.

p53 in nonneoplastic central nervous system lesions: an immunohistochemical and genetic sequencing study.

Kurtkaya-Yapicier O, Scheithauer BW, Hebrink D, James CD.

Neurosurgery. 2002 Nov;51(5):1246-54; discussion 1254-5.

PMID:
12383370
14.

Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas.

Mueller W, Lass U, Wellmann S, Kunitz F, von Deimling A.

Acta Neuropathol. 2005 Mar;109(3):314-20.

PMID:
15668788
15.

p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.

Tolbert DM, Noffsinger AE, Miller MA, DeVoe GW, Stemmermann GN, Macdonald JS, Fenoglio-Preiser CM.

Mod Pathol. 1999 Jan;12(1):54-60.

PMID:
9950163
16.

The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.

Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM.

Cancer Res. 1997 Jan 15;57(2):304-9.

17.

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

Erill N, Colomer A, Verdú M, Román R, Condom E, Hannaoui N, Banús JM, Cordon-Cardo C, Puig X.

Diagn Mol Pathol. 2004 Dec;13(4):217-23.

PMID:
15538112
18.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426.

19.

Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.

Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N.

Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.

PMID:
26171916
20.

p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ.

Am J Pathol. 1993 Nov;143(5):1389-97.

Supplemental Content

Support Center